Prof. Hiddo Heerspink: Insights from DAPA-CKD
Sep 01, 2020, 03:09 PM
In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink.
Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology examining the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.
In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink.
Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology examining the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.